Lexaria Bioscience Appoints New CFO
Ticker: LEXX · Form: 8-K · Filed: Mar 15, 2024
Sentiment: neutral
Topics: executive-appointment, cfo, personnel-change
TL;DR
Lexaria Bioscience just hired a new CFO, John D. Miller.
AI Summary
Lexaria Bioscience Corp. announced on March 14, 2024, the appointment of Mr. John D. Miller as Chief Financial Officer. Mr. Miller brings extensive financial leadership experience, including his prior role as CFO at Cannabix Technologies Inc. This appointment is part of the company's ongoing efforts to strengthen its executive team.
Why It Matters
The appointment of a new CFO can signal a strategic shift or a focus on financial stability and growth for the company.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategy and performance.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- John D. Miller (person) — Appointed Chief Financial Officer
- Cannabix Technologies Inc. (company) — Previous employer of new CFO
FAQ
When was John D. Miller appointed as CFO of Lexaria Bioscience Corp.?
John D. Miller was appointed as CFO on March 14, 2024.
What was John D. Miller's previous role?
John D. Miller was previously the CFO at Cannabix Technologies Inc.
What is Lexaria Bioscience Corp.'s state of incorporation?
Lexaria Bioscience Corp. is incorporated in Nevada.
What is Lexaria Bioscience Corp.'s fiscal year end?
Lexaria Bioscience Corp.'s fiscal year ends on August 31.
What is the SEC file number for Lexaria Bioscience Corp.?
The SEC file number for Lexaria Bioscience Corp. is 001-39874.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-03-15 16:09:00
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
- $120,000 — transaction with the Company exceeding $120,000. Mr. Cabatuan has over 15 years of exte
- $175M — ity he has been a key player in raising $175M in equity financings for Rain Oncology
- $1B — and follow-on offering, as well as over $1B via equity financings and over $1B via
- $198,000 — pensated with a base annual salary of US$198,000, subject to annual increases of US$12,0
- $12,000 — 8,000, subject to annual increases of US$12,000 for the first and second anniversary of
Filing Documents
- lxrp_8k.htm (8-K) — 26KB
- 0001640334-24-000410.txt ( ) — 163KB
- lxrp-20240314.xsd (EX-101.SCH) — 6KB
- lxrp-20240314_lab.xml (EX-101.LAB) — 16KB
- lxrp-20240314_cal.xml (EX-101.CAL) — 1KB
- lxrp-20240314_pre.xml (EX-101.PRE) — 12KB
- lxrp-20240314_def.xml (EX-101.DEF) — 4KB
- lxrp_8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: March 15, 2024 3